Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal

Biggest Award Yet, But Strategy Remains Unclear

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Novavax, Inc.’s efforts to develop a COVID-19 vaccine have received a huge boost from the US government’s Operation Warp Speed via a $1.6bn award.

The company had been one of a number of smaller companies chasing the leaders in the race to develop a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

29 Jul 2025

• By Mandy Jackson

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

29 Jul 2025

• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

29 Jul 2025

• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

29 Jul 2025

• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.